XNAS · MTVA
+2.05% · +$0.0300 · Vol 46.7K
After hours · updated 17:43:30 ET
MetaVia Inc. Common Stock

MetaVia Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$1.49
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
MTVA
MetaVia Inc. Common Stock
Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

52/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is MTVA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading MTVA catalysts
About MetaVia Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2016
Employees
8
Country
US

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.48
Day high
$1.51
Day low
$1.44
Previous close
$1.46
52W high
$16.50
-90.97% from high
52W low
$0.9700
3% of range
Market cap
$7.5M
EPS
$-1.5500
Beta
-0.25
Shares out
5.2M
Volume
46.7K
0.11× rel vol
Avg volume
418.4K
VWAP
$1.47
Price history computed in-house
1W
+3.47%
1M
-1.32%
3M
+12.03%
1Y
-77.42%
YTD
-82.30%
SMA 50 $1.84 · below
SMA 200 $3.96 · below
52W position 3%

MTVA overview

Veridion Score
52
4 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around MTVA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading MTVA Form 4 filings
Public disclosures

Congress activity in MTVA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for MTVA in the cached public ledger.

Federal contracts

MTVA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for MTVA in this window.
Lobbying spend

MTVA lobbying filings, year to date.

Registered lobbying filings matched to MetaVia Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for MTVA in this window.
Loading news for MTVA
Analyst ratings
Sovereign unlock shows live analyst consensus for MTVA.
Options
Sovereign unlock shows live options positioning for MTVA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.